Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during the European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder.
The post Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions appeared first on MedCity News.
© Copyright - BUSINESS REMARK - All Rights Reserved
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
